作者: Joseph W. Eschbach
DOI: 10.1007/978-94-009-1087-4_40
关键词: Urinary system 、 In vivo 、 Erythropoiesis 、 Iron deficiency 、 Erythropoietin 、 Hemodialysis 、 Peritoneal dialysis 、 Pharmacology 、 Anemia 、 Medicine
摘要: Recently, there have been numerous significant advances in our knowledge about the pathophysiology and management of anemia chronic renal failure. Aluminum, which dialysis patients receive as phosphate binders, can interfere with erythropoiesis (1, 2); evidence has presented to suggest that uremic inhibitors play a minor, if any, role causation (3, 4); an uremic, anemic sheep model corrected infusions plasma-rich erythropoietin (Epo) no vivo nor vitro erythroid marrow inhibition could be demonstrated (5, 6); finally, recombinant human (rHuEpo) reproduced by genetic technology methods shown clinical trials effective eliminating almost all hemodialysis it given (7, 8). The measurement Epo plasma is now easier more reliable use radioimmunoassays either urinary or Epo.